The authors conducted a randomized, double-blinded, multicenter, placebo-controlled trial in adults with mild COVID-19 to determine if favipiravir reduces the time to viral clearance. They found that favipiravir did not reduce the time to viral clearance within 15 days of starting the treatment.
|